Third of an eight-course sequence that prepares the student to provide patient-centered care by serving as a collaborative interprofessional team-member who is an authority on pharmacotherapy. This course also prepares the student to be a collaborative team member since learning involves teamwork. This course focuses on providing patient-centered care to patients who have cardiovascular and pulmonary disorders. Learners will develop, integrate, and apply knowledge from the foundational disciplines (i.e., pharmaceutical, social/behavioral/administrative, and clinical sciences) and apply the Pharmacists’ Patient Care Process in solving case-based scenarios of patients with cardiovascular and pulmonary diseases.

Teaching Partnership Leader

Priti N. Patel, Pharm.D., BCPS
- Email: ppatel@cop.ufl.edu
- Office: St. Petersburg Campus
- Phone: 727-394-6213
- Office Hours: By appointment ONLY.

See Appendix A. for Course Directory of Faculty and Staff Contact Information.

Entrustable Professional Activities

This course will prepare you to perform the following activities which the public entrusts a Pharmacist to perform:

1. EPA A1. Collect subjective and objective data by performing a patient assessment and gathering data from chart/electronic records, pharmacist records, other health professionals, and patient/family interviews.
2. EPA A2. Interpret patient data, identify medication-related problems, and develop a prioritized problem list.
5. EPA A5. Provide counseling and medications and health wellness (including referral when there are social determinants of health and disparities).
7. EPA A7. Present a succinct oral patient summary and plan to a health care provider. Defend a therapeutic plan verbally or in writing using references, guidelines, or primary literature.
9. EPA A9. Collaborate as a member of an interprofessional team and provide patient-centered care.

Course-Level Objectives

Upon completion of this course, the student will be able to:

1. **Provide patient-centered care for patients with one or more of the following disorders or pharmacotherapy needs:**
   a. Dyslipidemia
   b. Hypertension
   c. Anticoagulation
   d. Ischemic Heart Disease—Stable Angina Pectoris
   e. Acute Coronary Syndrome
   f. Chronic Heart Failure
   g. Arrhythmias—Atrial Fibrillation
   h. Asthma
   i. COPD
   j. Complicated Pneumonias

2. **Specifically, given a patient with one or more of the above disorders/pharmacotherapy needs:**
   a. **Integrate knowledge and use clinical reasoning skills in accomplishing the following steps when managing a patient with the disease state:**
      i. **Collect:** Gather subjective and objective information about the patient in order to understand the relevant medical and medication history and clinical status of the patient.
         1. Subjective and objective information is collected through patient interview, medical record review, pharmacy profile review, and communication with other members of the health care team.
         2. A Holistic View is initiated during collection in order to consider physiological, psychological, and sociological variables of the patient and this view is maintained throughout the patient care process.
      ii. **Assess:** Assess the information collected and analyze the clinical effects of the patient’s therapy in the context of the patient’s overall health goals in order to identify and prioritize problems and achieve optimal care.
         1. Understand, explain, and assess a patient’s health status.
         2. Interpret physical and patient assessment findings
         3. Assess each medication for appropriateness, effectiveness, safety, and patient adherence.
4. Assess health and functional status, risk factors, health data, cultural factors, health literacy, and access to medications or other aspects of care.
5. Assess immunization status and the need for preventive care and other health care services.
6. Integrate knowledge, clinical experience, and patient data to formulate and test hypotheses about the etiology of medication-related problems. (Generate hypotheses)
7. Establish potential and actual medication-related problems.

iii. Plan: Develop an individualized patient-centered care plan in collaboration with other health care professionals and the patient/caregiver.
1. Therapeutic Goals: Develop specific and general therapeutic goals for the patient. These goals achieve clinical outcomes in the context of the patient’s overall health care goals and access to care.
2. Therapeutic Plan: Integrate knowledge, evidence-based literature/information, clinical experience, patient data, patient goals and desires, and the prescriber’s judgment when developing the best pharmacotherapeutic plan for the patient.
   a. Therapeutic Alternatives: Evaluate pharmacotherapeutic alternatives for the patient before establishing the therapeutic plan.
   b. Develop the Therapeutic Plan: This plan addresses medication-related problems and optimizes medication therapy. Considerations for the plan include:
      i. Goals and desires of the patient
      ii. Application of established practice guidelines, evidence-based medicine, pharmacogenetics, and population-based treatment plans in developing the plan.
      iii. Accurate and patient-specific dosing (including dosage adjustment for renal/hepatic dysfunction, genotype, starting dose, maximum doses, timing of doses and pharmacokinetic design for narrow therapeutic index drugs,).
      iv. Parameters for monitoring response and frequency of monitoring
      v. Parameters for monitoring adverse effect and frequency of monitoring
      vi. Plan for patient counseling/education
      vii. Supports care continuity, including follow-up and transitions of care as appropriate.
   c. Patient/Caregiver engagement: The patient/caregiver are involved through education, empowerment, and self-management.
iv. **Implement**: Implement the care plan in collaboration with other health care professionals and the patient/caregiver. When implementing the care plan, the following are accomplished:

1. Medication and health-related problems are addressed.
2. Preventative care including vaccine administration are provided.
3. Medication therapy is initiated, modified, discontinued, or administered as authorized.
4. Education and self-management training is provided to the patient/caregiver.
5. Refers and provides transitions of care as needed.
6. Schedules follow-up care as needed to achieve goals of therapy.

v. **Follow-up (Monitor and Evaluate)**: Monitor and evaluate the effectiveness of the care plan and modify the plan in collaboration with other health care professionals and the patient/caregiver. The following are continually monitored and evaluated:

1. Medication appropriateness, effectiveness, and safety and patient adherence through available data, biometric test results and patient feedback.
2. Clinical endpoints that contribute to the patient’s overall health.
3. Outcomes of care, including progress toward or achievement of goals.

vi. **Patient-Centered Care**: Foster a patient-centered care approach by accomplishing the following:

1. **Communicate**: Succinctly communicate with other health care team members and the patient/caregiver throughout the patient care process.
2. **Collaborate**: Discuss with team members the specific therapeutic approaches for individual patients based on scientifically and logically validated assessment of the patient’s health care needs and an ethical consideration of the patient’s health care goals and desires.
3. **Document**: Prepare a written communication that is well-organized, logical, complete, appropriate, and evidence-based.

b. **Apply and integrate foundational knowledge (i.e., pharmaceutical, social/behavioral/administrative, and clinical sciences) throughout the patient care process.** This will require the ability to:

i. Describe the pathophysiology of disease state(s) and identify appropriate drug targets (cellular/molecular), biochemical processes, and organ changes for therapeutic intervention. Specifically, for a given disease state:

   1. Describe the basic pathophysiology of the disease including an explanation of the abnormal processes and the resulting disease signs and symptoms.
   2. Outline risk factors and/or diagnostic indicators (e.g., lab values, diagnostic test results).
   3. Determine classes of drugs that will treat the disease state and ameliorate the underlying pathophysiology and signs/symptoms.
ii. Apply knowledge about structure-activity relationships and cellular/molecular mechanisms of action to identify drug classes that are appropriate for treatment of the disease state. Specifically, for each drug class:
   1. Identify the relevant therapeutic targets and explain the mechanism(s) of action.

iii. Describe major pathways for metabolism and the pharmacological/therapeutic consequences of metabolism.

iv. Compare and contrast the therapeutic and adverse effects of drug classes that are appropriate for treating the disease state.
   1. Identify the most common/serious drug interactions and adverse effects.
   2. Identify important precautions and contraindications.

v. Compare and contrast the therapeutic and adverse effects of drugs within a given class and then recommend the best drug for the patient.

vi. Recommend any unique storage, handling, or use requirements to ensure patient safety and clinical efficacy.

vii. Discuss significant pharmacokinetic, pharmacogenetic, and pharmacodynamic considerations.

viii. Integrate the following transcending concepts when assessing a patient and developing a care plan:
   1. Apply foundational concepts about health information and informatics (Informatics)
   2. Evaluate cohort studies and apply to a patient need (Evidence-based practice)
   3. Use clinical reasoning and clinical judgment (Problem-solving)
   4. Address social considerations such as cultural sensitivity, health-related beliefs, health literacy, factors of a population including public health, access to care, quality, healthcare delivery, and policy (Social considerations)
   5. Consider patient/families behavioral considerations such as attitudes about health/wellness, adherence, effect of chronic illness, stress, and death and dying when providing care (Behavioral considerations).
   6. Communicate with patients, caregivers, and other health professionals.
   7. Consider pharmacists’ professional responsibilities including laws and ethics.
   9. Consider drug delivery systems.
   10. Apply pharmacokinetics pertinent to cardiovascular and pulmonary diseases.
   11. Apply pharmacogenomics (Personalized Medicine)
   12. Care for geriatric patients with cardiovascular and pulmonary diseases (Special populations)
   13. Assess the role of nonprescription/herbal products in the treatment of pulmonary disease (Self-care)
   14. Use SBAR when communicating with another health professional (Interprofessional collaboration)
   15. Consider medication safety for cardiovascular and pulmonary diseases
16. Consider pharmacokinetics for cardiovascular and pulmonary diseases
17. Apply population-based care for cardiovascular and pulmonary diseases

3. Demonstrate the ability to be an effective team member by collaborating in preparing for class sessions and in solving case studies.

**Course Pre-requisites**

1. Completion of all Year 1 Pharm.D. program coursework including milestones.
2. PHA5781C Patient Care I
3. PHA5782C Patient Care II
4. PHA5755 Principles of Medical Microbiology, Immunology, and Virology

**Course Co-requisites**

1. PHA5163L Professional Practice Skills Laboratory III

**Course Outline**

Please routinely check your campus calendar and the Canvas course site for any messages about changes in the schedule including meeting dates/times, deadlines, and room changes.

<table>
<thead>
<tr>
<th>Date Recommended Dates for Independent Study</th>
<th>Mod#</th>
<th>Unit Topic</th>
<th>Contact Hours [hr.]</th>
<th>Faculty Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>Module 0: Introduction to CV Modules (modules 1-6)</td>
<td>1.5hr</td>
<td></td>
</tr>
<tr>
<td>10/4/17</td>
<td>0.1</td>
<td>Unit 0.1: Introduction to CV Disease and Overview of Module</td>
<td>0.75hr</td>
<td>Cooper-DeHoff</td>
</tr>
<tr>
<td>10/4/17</td>
<td>0.2</td>
<td>Unit 0.2: General Cardiovascular Pathophysiology (Highlight of relevant material from 1PD year)</td>
<td>0.75hr</td>
<td>Keller-Wood</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>Module 1: Hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/5/17</td>
<td>1.1</td>
<td>Unit 1.1: Pathophysiology and Pharmacology: Autonomic Function, Sympathetic System Drug Classes: Beta Blockers and Calcium Channel Blockers</td>
<td>2.0hr</td>
<td>Frazier</td>
</tr>
<tr>
<td>Date</td>
<td>Mod#</td>
<td>Unit Topic</td>
<td>Contact Hours [hr.]a</td>
<td>Faculty Author</td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>10/5/17</td>
<td>1.2</td>
<td>Unit 1.2: Pathophysiology and Pharmacology: Renin Angiotensin System and volume Drug Classes: ACE inhibitors, ARBs, thiazide diuretics</td>
<td>2.0hr</td>
<td>Krause</td>
</tr>
<tr>
<td>10/9/17</td>
<td>1.3</td>
<td>Unit 1.3: Medicinal Chemistry Drug Classes: beta blockers, calcium channel blockers, ACE inhibitors, ARBS, thiazide diuretics</td>
<td>2.0hr</td>
<td>Aldrich</td>
</tr>
<tr>
<td>10/10/17</td>
<td>1.4</td>
<td>Unit 1.4: Pathophysiology of Hypertension</td>
<td>1.0hr</td>
<td>Keller-Wood</td>
</tr>
<tr>
<td>10/11/17</td>
<td></td>
<td>Intro and Unit 1.1-Unit 1.4 Q&amp;A Discussion: Pathophysiology, Pharmacology and Medicinal Chemistry of Drugs Covered in Intro 3 – Intro 5</td>
<td>1.0hr (2.0hr workup)</td>
<td>Cooper-DeHoff, Keller-Wood, Frazier, Krause and Aldrich</td>
</tr>
<tr>
<td>10/11/17</td>
<td>1.5</td>
<td>Unit 1.5: Pharmacotherapy and Management of Hypertension</td>
<td>2.0hr</td>
<td>Cooper-DeHoff</td>
</tr>
<tr>
<td>10/11/17</td>
<td>1.6</td>
<td>Unit 1.6: Transcending Concept: Social—Fighting Obesity; Health Disparities; Hypertension</td>
<td>1.0hr</td>
<td>Motycka</td>
</tr>
<tr>
<td>10/11/17</td>
<td>1.7</td>
<td>Unit 1.7: Transcending Concept: Health-Wellness—Hypertension</td>
<td>0.5hr</td>
<td>Vogel-Anderson</td>
</tr>
<tr>
<td>10/13/17</td>
<td></td>
<td>Intro, Unit 1.1 – Unit 1.7 Active Learning Session 1: Case Studies – Hypertension Readiness Assessment Test #1 Review Module Concepts as Needed Team Based Learning Application</td>
<td>2.0hr (4.0hr workup)</td>
<td>Cooper-DeHoff, Motycka, Keller-Wood, Krause, Frazier, Aldrich, Vogel-Anderson</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>Module 2: Dyslipidemia</td>
<td>6.75hr</td>
<td></td>
</tr>
<tr>
<td>10/16/17</td>
<td>2.1</td>
<td>Unit 2.1: Dyslipidemia – Lipid Metabolism</td>
<td>0.75hr</td>
<td>Miller</td>
</tr>
<tr>
<td>10/16/17</td>
<td>2.2</td>
<td>Unit 2.2: Pharmacology of Antihyperlipidemc</td>
<td>1.0hr</td>
<td>Miller</td>
</tr>
<tr>
<td>Date</td>
<td>Mod#</td>
<td>Unit Topic</td>
<td>Contact Hours [hr.]a</td>
<td>Faculty Author</td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>10/16/17</td>
<td>2.3</td>
<td>Unit 2.3: Medicinal Chemistry of Antihyperlipidemics</td>
<td>0.75hr</td>
<td>Huigens</td>
</tr>
<tr>
<td>10/17/17</td>
<td>2.4</td>
<td>Unit 2.4: Management of Dyslipidemia</td>
<td>1.5hr</td>
<td>Cooper-DeHoff</td>
</tr>
<tr>
<td>10/17/17</td>
<td>2.5</td>
<td>Unit 2.5: Transcending Concept: Health Information and Informatics—HIT Supporting Outpatient Drug Use</td>
<td>0.75hr</td>
<td></td>
</tr>
<tr>
<td>10/18/17</td>
<td>2.1 – 2.5</td>
<td>Active Learning Session 2: Case Studies – Dyslipidemia Readiness Assessment Test #2 Review Module Concepts as Needed Team Based Learning Application</td>
<td>2.0hr (4.0hr workup)</td>
<td>Miller, Huigens, Cooper-DeHoff</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Module 3: Ischemic Heart Disease</td>
<td>5.25hr</td>
<td></td>
</tr>
<tr>
<td>10/19/17</td>
<td>3.1</td>
<td>Unit 3.1: Pharmacology and Medicinal Chemistry of Nitrodilators</td>
<td>1.0hr</td>
<td>Ding</td>
</tr>
<tr>
<td>10/19/17</td>
<td>3.2</td>
<td>Unit 3.2: Management of Ischemic Heart Disease</td>
<td>1.25hr</td>
<td>Duarte</td>
</tr>
<tr>
<td>10/19/17</td>
<td>3.3</td>
<td>Unit 3.3: Transcending Concept: Personalized Medicine—Cardiovascular Diseases</td>
<td>0.5hr</td>
<td>Cavallari</td>
</tr>
<tr>
<td>10/19/17</td>
<td>3.4</td>
<td>Unit 3.4: Transcending Concept: EBP: Cardiovascular Clinical Trials</td>
<td>0.5hr</td>
<td>Patel</td>
</tr>
<tr>
<td>10/20/17</td>
<td>1.2-1.4 and 3.1-3.3</td>
<td>Active Learning Session 3: Case Studies – Ischemic Heart Disease Readiness Assessment Test #3 Review Module Concepts as Needed Team Based Learning Application</td>
<td>2.0hr (4.0hr workup)</td>
<td>Keller-Wood, Ding, Duarte, Cavallari, Patel</td>
</tr>
<tr>
<td>10/23/17</td>
<td>Intro-Module 3</td>
<td>Exam 1: Intro-Module 3</td>
<td>2.5hr</td>
<td></td>
</tr>
<tr>
<td>10/24/17</td>
<td>4.1</td>
<td>Unit 4.1: Pathophysiology of Blood Clotting</td>
<td>1.0hr</td>
<td>Vogel-Anderson</td>
</tr>
<tr>
<td>Date</td>
<td>Mod#</td>
<td>Unit Topic</td>
<td>Contact Hours [hr.]a</td>
<td>Faculty Author</td>
</tr>
<tr>
<td>------------------</td>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>10/24/17</td>
<td>4.2</td>
<td>Unit 4.2: Pharmacology of Anticoagulants, Fibrinolytic Agents, and Antiplatelet Therapy</td>
<td>2.0hr</td>
<td>Voils</td>
</tr>
<tr>
<td>10/25/17</td>
<td>4.3</td>
<td>Unit 4.3: Medicinal Chemistry of Anticoagulants, Fibrinolytic Agents, and Antiplatelet Therapy</td>
<td>1.0hr</td>
<td>Ding</td>
</tr>
<tr>
<td>10/25/17</td>
<td>4.4</td>
<td>Unit 4.4: Management of Acute Coronary Syndrome</td>
<td>1.0hr</td>
<td>Vogel-Anderson</td>
</tr>
<tr>
<td>10/26/17 8:30am-12:35pm</td>
<td>1A.2-4.4</td>
<td>Active Learning Session 4: Case Studies – Acute Coronary Syndrome Readiness Assessment Test #4 Review Module Concepts as Needed Team Based Learning Application</td>
<td>2.0hr (4.0hr workup)</td>
<td>Vogel-Anderson, Voils, Ding</td>
</tr>
<tr>
<td>10/26/17 10:40am-12:35pm</td>
<td>Thru 5.2</td>
<td>Active Learning Session 5: Case Studies – Pathophysiology of Heart Failure Readiness Assessment Test #5 Review Module Concepts as Needed Team Based Learning Application</td>
<td>1.0hr (2.0hr workup)</td>
<td>Keller-Wood</td>
</tr>
<tr>
<td>10/26/17 1:55-6:00pm</td>
<td>1A.2-5.5</td>
<td>Active Learning Session 6: Case Studies – Heart Failure Readiness Assessment Test #6 Review Module Concepts as Needed Team Based Learning Application</td>
<td>2.0hr (4.0hr workup)</td>
<td>Keller-Wood, Ding, Cavallari, Vogel-Anderson, Segal</td>
</tr>
<tr>
<td>10/27/17 10:40am-12:35pm</td>
<td>5.1-5.5</td>
<td>Unit 5.1: Pathophysiology of Heart Failure</td>
<td>2.0hr</td>
<td>Keller-Wood</td>
</tr>
<tr>
<td>10/27/17 9:55-12:35pm</td>
<td>Thru 5.2</td>
<td>Unit 5.2: Pharmacology of Inotropic Agents, Glycosides, Neprilysin Inhibitors, Aldosterone Antagonists</td>
<td>1.25hr</td>
<td>Ding</td>
</tr>
<tr>
<td>10/27/17 1:55-6:00pm</td>
<td>5.3-5.5</td>
<td>Unit 5.3: Medicinal Chemistry of Inotropic Agents, Glycosides, Aldosterone Antagonists</td>
<td>1.25hr</td>
<td>Ding</td>
</tr>
<tr>
<td>10/27/17 1:55-6:00pm</td>
<td>5.4-5.5</td>
<td>Unit 5.4: Management of Chronic Heart Failure (HFrEF &amp; HFpEF)</td>
<td>2.0hr</td>
<td>Cavallari</td>
</tr>
<tr>
<td>10/27/17 1:55-6:00pm</td>
<td>5.5-5.5</td>
<td>Unit 5.5: Transcending Concept: Medication Safety—Medication Reconciliation</td>
<td>1.0hr</td>
<td>Vogel Anderson, Segal</td>
</tr>
<tr>
<td>10/27/17 1:55-6:00pm</td>
<td>5.6-5.5</td>
<td>Active Learning Session 6: Case Studies – Heart Failure Readiness Assessment Test #6 Review Module Concepts as Needed Team Based Learning Application</td>
<td>2.0hr (4.0hr workup)</td>
<td>Keller-Wood, Ding, Cavallari, Vogel-Anderson, Segal</td>
</tr>
<tr>
<td>Date</td>
<td>Mod#</td>
<td>Unit Topic</td>
<td>Contact Hours [hr.]</td>
<td>Faculty Author</td>
</tr>
<tr>
<td>--------------------</td>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>10/30/17</td>
<td>6.1</td>
<td>Unit 6.1: Individualized Heparin and Warfarin Dosing</td>
<td>1.0hr</td>
<td>Vogel-Anderson</td>
</tr>
<tr>
<td>10/31/17</td>
<td>6.2</td>
<td>Unit 6.2: Pathophysiology of Arrhythmias</td>
<td>0.75hr</td>
<td>Keller-Wood</td>
</tr>
<tr>
<td>10/31/17</td>
<td>6.3</td>
<td>Unit 6.3: Introduction to Electrocardiology</td>
<td>0.75hr</td>
<td>Vogel-Anderson</td>
</tr>
<tr>
<td>10/31/17</td>
<td>6.4</td>
<td>Unit 6.4: Pharmacology of Antiarrhythmics</td>
<td>1.0hr</td>
<td>Vogel-Anderson</td>
</tr>
<tr>
<td>11/1/17</td>
<td>6.5</td>
<td>Unit 6.5: Medicinal Chemistry of Antiarrhythmics</td>
<td>1.0hr</td>
<td>Ding</td>
</tr>
<tr>
<td>11/1/17</td>
<td>6.6</td>
<td>Unit 6.6: Management of Arrhythmias</td>
<td>1.0hr</td>
<td>Vogel-Anderson</td>
</tr>
<tr>
<td>11/1/17</td>
<td>6.7</td>
<td>Unit 6.7: Pharmacokinetics of Digoxin and Antiarrhythmics</td>
<td>0.5hr</td>
<td>Bihorel</td>
</tr>
<tr>
<td>11/2/17</td>
<td>Thru 6.7</td>
<td>Q &amp; A: Anticoagulation &amp; Arrhythmias</td>
<td>1.0hr</td>
<td>Vogel-Anderson</td>
</tr>
<tr>
<td>11/6/17</td>
<td>Thru 6.7</td>
<td>Active Learning Session #7: Case Studies - Atrial Fibrillation</td>
<td>2.0hr (4.0hr workup)</td>
<td>Keller-Wood, Vogel-Anderson, Ding, Bihorel</td>
</tr>
<tr>
<td>11/8/17</td>
<td>4-6</td>
<td>Exam 2: Modules 4-6</td>
<td>2.5hr</td>
<td></td>
</tr>
<tr>
<td>11/8/17</td>
<td>7</td>
<td>Module 7: Asthma</td>
<td>8.5hr</td>
<td></td>
</tr>
<tr>
<td>11/8/17</td>
<td>7.1</td>
<td>Unit 7.1: Pathophysiology of Asthma</td>
<td>0.5hr</td>
<td>Farland</td>
</tr>
<tr>
<td>11/9/17</td>
<td>7.2</td>
<td>Unit 7.2: Pharmacology of Oral and Inhaled Corticosteroids, Short-acting Beta-agonists, Long-acting Beta-agonists, Muscarinic Agents</td>
<td>2.0hr</td>
<td>Hochhaus</td>
</tr>
<tr>
<td>Date</td>
<td>Mod#</td>
<td>Unit Topic</td>
<td>Contact Hours</td>
<td>Faculty Author</td>
</tr>
<tr>
<td>--------------------</td>
<td>------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>11/9/17</td>
<td>7.3</td>
<td>Unit 7.3: Medicinal Chemistry of Oral and Inhaled Corticosteroids, Short-acting Beta-agonists, Long-acting Beta-agonists, Muscarinic Agents</td>
<td>1.5hr</td>
<td>Aldrich</td>
</tr>
<tr>
<td>11/10/17</td>
<td>7.4</td>
<td>Unit 7.4: Management of Chronic Asthma</td>
<td>1.5hr</td>
<td>Farland</td>
</tr>
<tr>
<td>11/10/17</td>
<td>7.5</td>
<td>Unit 7.5: Transcending Concept: Personalized Medicine—Asthma</td>
<td>0.5hr</td>
<td>McDonough</td>
</tr>
<tr>
<td>11/13/17 8:30am-12:35pm</td>
<td>Thru 7.5</td>
<td>Active Learning Session 8: <em>Case Studies – Asthma</em>&lt;br&gt;Readiness Assessment Test #8&lt;br&gt;Review Module Concepts as Needed&lt;br&gt;Team Based Learning Application</td>
<td>2.0hr (4.0hr workup)</td>
<td>Farland, Hochhaus, Aldrich, McDonough</td>
</tr>
<tr>
<td>11/14/17</td>
<td>8.1</td>
<td>Unit 8.1: Pathophysiology of COPD</td>
<td>0.5hr</td>
<td>Farland</td>
</tr>
<tr>
<td>11/14/17</td>
<td>8.2</td>
<td>Unit 8.2: Management of COPD</td>
<td>1.0hr</td>
<td>Farland</td>
</tr>
<tr>
<td>11/15/17</td>
<td>8.3</td>
<td>Unit 8.3: Transcending Concepts: Health-Wellness—Smoking Cessation</td>
<td>1.0hr</td>
<td>Talona</td>
</tr>
<tr>
<td>11/15/17</td>
<td>8.4</td>
<td>Unit 8.4: Transcending Concept: Motivational Interviewing ComMit (Module 3)</td>
<td>0.75hr</td>
<td>M. Ziegler</td>
</tr>
<tr>
<td>11/16/17</td>
<td>8.5</td>
<td>Unit 8.5: Transcending Concept: Population-based Care &amp; Pharmacoeconomics CEA and PROs in asthma product evaluation; value-based drug formularies (Regence example)</td>
<td>1.0hr</td>
<td>Navarro</td>
</tr>
<tr>
<td>11/16/17</td>
<td>8.6</td>
<td>Unit 8.6: Transcending Concepts: Special Populations—Geriatric Drug Dosing</td>
<td>0.5hr</td>
<td>Miller</td>
</tr>
<tr>
<td>11/16/17</td>
<td>8.7</td>
<td>Unit 8.7: Transcending Concept: Evidence-Based Practice—Cohort Studies and Confounding and Bias</td>
<td>1.0hr</td>
<td>Wei</td>
</tr>
<tr>
<td>11/17/17 1:55-6:00pm</td>
<td>Thru 8.7</td>
<td>Active Learning Session 9: <em>Case Studies – COPD</em>&lt;br&gt;Readiness Assessment Test #9&lt;br&gt;Review Module Concepts as Needed&lt;br&gt;Team Based Learning Application</td>
<td>2.0hr (4.0hr workup)</td>
<td>Farland, Hochhaus, Aldrich, Navarro</td>
</tr>
<tr>
<td>Date</td>
<td>Recommended Dates for Independent Study</td>
<td>Mod#</td>
<td>Unit Topic</td>
<td>Contact Hours [hr.]</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------</td>
<td>------</td>
<td>----------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>11/17/17</td>
<td>9</td>
<td>9.1</td>
<td>Unit 9.1: Hospital-Acquired &amp; Ventilator-Associated Pneumonias</td>
<td>1.5hr</td>
</tr>
<tr>
<td>11/17/17</td>
<td>9.2</td>
<td></td>
<td>Unit 9.2: Transcending Concepts: Self-Care—Cough &amp; Cold (re-enforce from Patient Care 1)</td>
<td>0.5hr</td>
</tr>
<tr>
<td>11/17/17</td>
<td>9.3</td>
<td></td>
<td>Unit 9.3: Transcending Concept: Interprofessional Communication - Listen actively, and encourage ideas and opinions of other interprofessional team members.</td>
<td>1.0hr</td>
</tr>
<tr>
<td>11/20/17</td>
<td>9.4</td>
<td></td>
<td>Unit 9.4: Tuberculosis</td>
<td>2.0hr</td>
</tr>
<tr>
<td>11/20/17</td>
<td>9.5</td>
<td></td>
<td>Unit 9.5: Lung Cancer</td>
<td>1.0hr</td>
</tr>
<tr>
<td>11/27/17</td>
<td>Thru 9.3</td>
<td></td>
<td>Active Learning Session 10: Case Studies — Respiratory Conditions</td>
<td>2.0hr (4.0hr workup)</td>
</tr>
<tr>
<td>11/28/17</td>
<td>10</td>
<td></td>
<td>Module 10: Capstone</td>
<td>2.0hr</td>
</tr>
<tr>
<td>11/29/17</td>
<td>10.1</td>
<td></td>
<td>Unit 10.1: Transcending Concept: Professionalism—Ethics and Law</td>
<td>2.0hr</td>
</tr>
<tr>
<td>12/1/17</td>
<td>All Modules</td>
<td></td>
<td>Exam 3: All Modules</td>
<td>2.5hr</td>
</tr>
</tbody>
</table>
Required Textbooks/Readings

   - Previously purchased for PHA5782C
   - Not Available via HSC Library
   - Previously purchased for PHA5782C
   - Not Available via HSC Library
   - Previously used for PHA5782C
   - Available via HSC Library – Access Pharmacy
   - Previously used for PHA5782C
   - Available via HSC Library – Access Pharmacy
5. Primary literature readings will be posted in Canvas.

Use UF VPN to access UF Libraries Resources when off-campus. The UF HSC library staff can assist you with questions or issues related to accessing online library materials. For assistance contact your College of Pharmacy librarian or visit the HSC Library Website at this URL: http://www.library.health.ufl.edu/

Suggested Textbooks/Readings

There are no suggested textbooks for this course.

Other Required Learning Resources

N/A

Materials & Supplies Fees

None
**Student Evaluation & Grading**

Evaluation Methods and How Grades are calculated.

<table>
<thead>
<tr>
<th>Assessment Item</th>
<th>Grade Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>iRATs [9]</td>
<td>10%</td>
</tr>
<tr>
<td>tRATs [10]</td>
<td>20%</td>
</tr>
<tr>
<td>Exam 1</td>
<td>20%</td>
</tr>
<tr>
<td>Exam 2</td>
<td>20%</td>
</tr>
<tr>
<td>Exam 3</td>
<td>30%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

**Table 1. Grading Scale**

<table>
<thead>
<tr>
<th>Percentage Range</th>
<th>Letter Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>92.50-100%</td>
<td>A</td>
</tr>
<tr>
<td>89.50-92.49%</td>
<td>A-</td>
</tr>
<tr>
<td>86.50-89.49%</td>
<td>B+</td>
</tr>
<tr>
<td>82.50-86.49%</td>
<td>B</td>
</tr>
<tr>
<td>79.50-82.49%</td>
<td>B-</td>
</tr>
<tr>
<td>76.50-79.49%</td>
<td>C+</td>
</tr>
<tr>
<td>72.50-76.49%</td>
<td>C</td>
</tr>
<tr>
<td>69.50-72.49%</td>
<td>C-</td>
</tr>
<tr>
<td>66.50-69.49%</td>
<td>D+</td>
</tr>
<tr>
<td>62.50-66.49%</td>
<td>D</td>
</tr>
<tr>
<td>59.50-62.49%</td>
<td>D-</td>
</tr>
<tr>
<td>&lt; 59.50%</td>
<td>E</td>
</tr>
</tbody>
</table>

**Rounding of grades:**

Final grades in Canvas will be rounded to the 2nd decimal place. If the decimal is X.495 or higher, Canvas will round the grade to X.50. The above scale depicts this policy and grades are determined accordingly. Grade assignment is made using this policy and NO EXCEPTIONS will be made in situations where a student’s grade is “close.”

**Educational Technology Use**

The following technology below will be used during the course and the student must have the appropriate technology and software.

1. ExamSoft™ Testing Platform
2. Canvas™ Learning Management System

For technical support, navigate to Educational Technology and IT Support Contact Information at this URL: http://curriculum.pharmacy.ufl.edu/current-students/technical-help/

**Pharm.D. Course Policies**

The Policies in the following link apply to this course. Review the Pharm.D. Course Policies carefully, at this URL: http://curriculum.pharmacy.ufl.edu/current-students/course-policies/
Appendix A. Course Directory

Teaching Partnership Leader/Course Director:

Priti N. Patel, Pharm.D., BCPS
Email: ppatel@cop.ufl.edu
Office: St. Petersburg Campus
Phone: 727-394-6213

Questions to Ask:
- Questions about grades
- Concerns about performance
- Guidance when there are performance problems (failing grades)
- General questions about content

Academic Coordinator:

Name: Sarah Burgess, M.Ed
Email: sburgess@cop.ufl.edu
Office: HPNP 4312
Phone: 352-273-5617
Absence Email: absent2pd@cop.ufl.edu

Educational Coordinators:

Name: McKenzie Wallen Email: mwallen@cop.ufl.edu
Office: Jacksonville Campus

Name: Victoria Savosh Email: vsavosh@cop.ufl.edu
Office: Orlando Campus

Questions to Ask:
- Issues related to course policies (absences, make up exams, missed attendance)
- Absence requests (Only the Academic Coordinator handles absence requests)
- Questions about dates, deadlines, meeting place
- Availability of handouts and other course materials
- Assignment directions
- Questions about grade entries gradebook (missing grades, wrong grade)
- Assistance with ExamSoft® (Distant campus students may contact Education Coordinator for use of SofTest and assistance during exams. The Academic Coordinator is the contact person for issues related to grading and posting of ExamSoft grades.)
Other Teaching Partnership Faculty Members:

Jane Aldrich, Ph.D.
Email: jaldrich@cop.ufl.edu
Office: HSC P4-27
Phone: 352-273-8708

Lori Dupree, Pharm.D., BCPS
Email: ldupree@cop.ufl.edu
Office: JAX
Phone: 904-244-9590

William Allen, J.D., M.Div.
Email: wmallen@ufl.edu
Office:
Phone: 352-273-5155

Michelle Farland, Pharm.D., BCPS, CDE
Email: mfarland@cop.ufl.edu
Office: HPNP 3307
Phone: 352-273-6293

Sihem Bihorel, Ph.D., Pharm.D., M.S.
Email: sihem.bihorel@ufl.edu
Office: ORL 469
Phone: 407-313-7037

Charles Frazier, Ph.D.
Email: frazier@cop.ufl.edu
Office: HSC P2-29
Phone: 352-273-7686

Larisa Cavallari, Pharm.D.
Email: lcavallari@cop.ufl.edu
Office: HSC PG-22A
Phone: 352-273-8245

Guenther Hocchaus, Ph.D.
Email: hocchaus@cop.ufl.edu
Office: HSC P3-33
Phone: 352-273-7861

Stacey Curtis, Pharm.D.
Email: scurtis@cop.ufl.edu
Office:
Phone: 352-273-6228

Robert Huigens III, Ph.D.
Email: rwhuigens@ufl.edu
Office: HSC P5-33
Email: 352-273-7718

Rhonda Cooper-DeHoff, Pharm.D., M.S. FAHA, FACC
Email: dehoff@cop.ufl.edu
Office: HSC PG-25
Phone: 352-273-6184

Jackie Jourjy, Pharm.D., BCPS
Email: jjourjy@cop.ufl.edu
Office: Lake Nona/ORL
Phone: 407-313-7006

Yousong Ding, Ph.D.
Email: yding@cop.ufl.edu
Office: HSC P6-27
Phone: 352-273-7742

Maureen Keller-Wood, Ph.D.
Email: kellerwd@cop.ufl.edu
Office: HPNP 4332A
Phone: 352-273-7687

Julio Duarte, Pharm.D., Ph.D.
Email: juliod@cop.ufl.edu
Office: HSC PG-21
Phone: 352-273-8132

Eric Krause, Ph.D.
Email: ekrause@cop.ufl.edu
Office: HSC P-2-27
Phone: 352-273-6977
Paige May, Pharm.D.
Email: paige.may@va.gov
Office: VA/GNV
Phone: 352-548-6000, ext. 4426

Richard Segal, Ph.D.
Email: segal@ufl.edu
Office: HPNP 4332
Phone: 352-273-6265

Caitrin McDonough, Ph.D.
Email: cmcdonough@cop.ufl.edu
Office: HSC PG-05B
Phone: 352-273-6435

Katie Vogel Anderson, Pharm.D., BCACP
Email: kvanderson@cop.ufl.edu
Office: HPNP 3313
Phone: 352-273-6413

Shannon Miller, Pharm.D., BCACP
Email: smiller@cop.ufl.edu
Office: ORL
Phone: 407-313-7031

Stacy Voils, Pharm.D., M.S., BCPS, FCCM, FCCP
Email: svoils@cop.ufl.edu
Office: HPNP 3315
Phone: 352-294-5276

Carol Motycka, Pharm.D., BCACP
Email: motycka@cop.ufl.edu
Office: JAX
Phone: 904-244-9590

Yu-Jung (Jenny) Wei, Ph.D., M.S.
Email: jenny.wei@cop.ufl.edu
Office: HPNP 3321
Phone: 352-294-5340

Robert Navarro, Pharm.D.
Email: rnavarro@cop.ufl.edu
Office: HPNP 2338
Phone: 352-273-5526

Charles Peloquin, Pharm.D.
Email: peoloquin@cop.ufl.edu
Office: HSC P4-33
Phone: 352-273-6266

Teresa Roane, Pharm.D., BCACP
Email: troane@cop.ufl.edu
Office: HPNP 2300
Phone: 352-273-9692

Anzeela Schentrup, Pharm.D., Ph.D., BCPS
Email: schena@shands.ufl.edu
Office: 1329 SW 16th St. Rm. 2165
Phone: 352-265-8309